A detailed history of Quantbot Technologies LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Quantbot Technologies LP holds 2,614 shares of HALO stock, worth $138,019. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,614
Holding current value
$138,019
% of portfolio
0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$51.3 - $64.42 $134,098 - $168,393
2,614 New
2,614 $149,000
Q4 2022

Feb 13, 2023

BUY
$40.06 - $59.44 $267,720 - $397,237
6,683 New
6,683 $380,000
Q2 2022

Aug 09, 2022

BUY
$37.35 - $48.3 $242,775 - $313,950
6,500 New
6,500 $286,000
Q4 2021

Feb 11, 2022

SELL
$31.82 - $40.75 $116,461 - $149,145
-3,660 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$38.47 - $46.42 $72,708 - $87,733
-1,890 Reduced 34.05%
3,660 $148,000
Q2 2021

Aug 12, 2021

SELL
$38.84 - $51.31 $49,171 - $64,958
-1,266 Reduced 18.57%
5,550 $252,000
Q1 2021

May 14, 2021

BUY
$39.51 - $51.45 $8,178 - $10,650
207 Added 3.13%
6,816 $284,000
Q4 2020

Feb 12, 2021

BUY
$25.81 - $43.62 $72,371 - $122,310
2,804 Added 73.69%
6,609 $282,000
Q3 2020

Nov 16, 2020

BUY
$25.74 - $29.63 $68,442 - $78,786
2,659 Added 232.02%
3,805 $99,000
Q2 2020

Aug 13, 2020

BUY
$16.25 - $26.81 $14,040 - $23,163
864 Added 306.38%
1,146 $30,000
Q1 2020

May 13, 2020

SELL
$13.9 - $21.83 $31,678 - $49,750
-2,279 Reduced 88.99%
282 $5,000
Q4 2019

Feb 10, 2020

BUY
$14.93 - $19.53 $23,305 - $30,486
1,561 Added 156.1%
2,561 $45,000
Q3 2019

Nov 12, 2019

SELL
$15.2 - $17.69 $9,120 - $10,614
-600 Reduced 37.5%
1,000 $15,000
Q2 2019

Aug 13, 2019

BUY
$14.75 - $17.26 $23,600 - $27,616
1,600 New
1,600 $27,000
Q4 2018

Feb 13, 2019

SELL
$13.33 - $18.66 $46,788 - $65,496
-3,510 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$16.68 - $18.41 $58,546 - $64,619
3,510 New
3,510 $63,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.35B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.